Natrol
This article was originally published in The Tan Sheet
Executive Summary
Fourth quarter sales expected to fall roughly 13.3% to $15.6 mil. from $18 mil. in year-ago period, according to preliminary results released Feb. 8. Net sales for 2001 should reach about $76.2 mil., down 12.5%, firm reports. Natrol attributes decline to weakening drug channel, higher returns. Chatsworth, Calif.-based firm notes it will take a $20 mil. impairment charge for 2001, writing down the value of goodwill associated with its 1999 acquisition of Prolab Nutrition, which has posted disappointing financials...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.